Hyperpolarized 129Xe MRI for Pulmonary Hypertension
Pulmonary Hypertension SOLAR
Recruiting
Phase 2
Interventional Study
Interstitial Lung Disease
COPD
Pulmonary Arterial Hypertension
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 30 (estimated)
- Sponsor
- Bastiaan Driehuys · Other
Who this trial is looking for
This trial is looking for adults who are on the lung transplant waiting list at Duke University Medical Center and have specific types of pulmonary hypertension. Participants will help develop a noninvasive imaging technique to better understand their condition.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old.
- I am on the lung transplant waiting list at Duke University Medical Center.
- I have pulmonary hypertension.
- I have COPD or interstitial lung disease.
- I can give informed consent and follow the study schedule.
You may not be able to join if
- I have moderate to severe heart disease.
- I have sarcoidosis.
- I have active cancer.
- I have sickle cell anemia.
- I have liver disease.
- I am a prisoner or pregnant.
- I cannot give consent.
- I have conditions preventing me from having an MRI.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic "ground truth" correlat…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age ≥ 18 years' old
2. Be on the lung transplant waiting list at Duke University Medical Center.
3. PH as defined by RHC - mPAP \> 20 mmHg, PVR \> 3 WU, PCWP \< 15 mmHg
4. Groups defined as:
PAH: Clinical diagnosis of PAH (Group 1 PH) in the absence of severe chronic lung…
Contacts